Kenvue (NYSE:KVUE) Updates Q2 2025 Earnings Guidance

Kenvue (NYSE:KVUE - Get Free Report) issued an update on its second quarter 2025 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of 0.280-0.290 for the period, compared to the consensus estimate of 0.279. The company issued revenue guidance of -.

Kenvue Stock Performance

KVUE traded down $0.22 on Tuesday, hitting $21.60. The company had a trading volume of 7,749,313 shares, compared to its average volume of 16,209,683. The company's fifty day moving average price is $22.34 and its 200 day moving average price is $22.30. Kenvue has a 1-year low of $17.85 and a 1-year high of $25.17. The company has a debt-to-equity ratio of 0.63, a current ratio of 0.86 and a quick ratio of 0.60. The stock has a market cap of $41.44 billion, a price-to-earnings ratio of 39.23, a price-to-earnings-growth ratio of 3.32 and a beta of 0.83.

Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.24 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The business had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. During the same period in the prior year, the company posted $0.28 earnings per share. Kenvue's revenue was down 3.9% on a year-over-year basis. Equities analysts predict that Kenvue will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th were issued a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.80%. The ex-dividend date was Wednesday, May 14th. Kenvue's dividend payout ratio is 149.09%.

Analysts Set New Price Targets

A number of brokerages have issued reports on KVUE. Redburn Atlantic began coverage on Kenvue in a report on Thursday, April 10th. They set a "neutral" rating and a $23.50 target price on the stock. Bank of America reduced their target price on Kenvue from $27.00 to $25.00 and set a "buy" rating on the stock in a report on Tuesday. Citigroup reaffirmed a "neutral" rating on shares of Kenvue in a research report on Friday, June 13th. Barclays raised their price target on Kenvue from $22.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Monday, May 12th. Finally, Evercore ISI began coverage on Kenvue in a research report on Monday, March 24th. They issued an "in-line" rating and a $25.00 target price on the stock. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $25.17.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.